Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop
Plain English summary Patients with rare diseases often help to develop new treatments for their conditions. But once developed, those treatments are sometimes priced too high for many patients to access them. We became aware that this is a problem in the course of a social science research project...
Main Authors: | Koichi Mikami, Steve Sturdy |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Research Involvement and Engagement |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40900-017-0065-z |
Similar Items
-
Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01) -
Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025
by: Richard Lech, et al.
Published: (2022-10-01) -
Patient access to orphan drugs in France
by: Marion Bourdoncle, et al.
Published: (2019-02-01) -
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
by: Kathleen L. Miller, et al.
Published: (2021-06-01) -
Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
by: Bander Balkhi, et al.
Published: (2023-09-01)